Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
1140 participants
INTERVENTIONAL
2006-11-30
2014-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer
NCT00312377
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
NCT00364351
ZD6474 in Treating Patients With Small Cell Lung Cancer
NCT00066313
Zactima in Non Small Cell Lung Cancer (NSCLC) ELderly Patients In Combination With or Versus Gemcitabine
NCT00753714
ZD6474 Phase IIa Dose Finding Multicentre Study
NCT00252746
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Best Supportive Care
Best Supportive Care
standard of care
2
Vandetanib + Best Supportive Care
ZD6474 (vandetanib)
once daily oral tablet
Best Supportive Care
standard of care
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ZD6474 (vandetanib)
once daily oral tablet
Best Supportive Care
standard of care
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Three or more prior chemotherapy regimens.
* Significant cardiovascular events.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Genzyme, a Sanofi Company
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Sciences & Operations
Role: STUDY_DIRECTOR
Sanofi
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Tucson, Arizona, United States
Research Site
Germantown, Tennessee, United States
Research Site
Bahía Blanca, , Argentina
Research Site
Ciudad de Buenos Aires, , Argentina
Research Site
La Plata, , Argentina
Research Site
Rosario, , Argentina
Research Site
San Miguel de Tucumán, , Argentina
Research Site
Santa Fe, , Argentina
Research Site
Fitzroy, , Australia
Research Site
Perth, , Australia
Research Site
St Leonards, , Australia
Research Site
Tugan, , Australia
Research Site
Woodville South, , Australia
Research Site
Linz, , Austria
Research Site
Salzburg, , Austria
Research Site
Vienna, , Austria
Research Site
Antwerp, , Belgium
Research Site
Brussels (Woluwé-St-Lambert), , Belgium
Research Site
Charleroi, , Belgium
Research Site
Edegem, , Belgium
Research Site
Ghent, , Belgium
Research Site
Leuven, , Belgium
Research Site
Liège, , Belgium
Research Site
Edmonton, Alberta, Canada
Research Site
Oshawa, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Beijing, , China
Research Site
Chengdu, , China
Research Site
Dalian, , China
Research Site
Guangzhou, , China
Research Site
Nanjing, , China
Research Site
Shanghai, , China
Research Site
Wuhan, , China
Research Site
Xi'an, , China
Research Site
Brest, , France
Research Site
Caen, , France
Research Site
Lyon, , France
Research Site
Marseille, , France
Research Site
Nice, , France
Research Site
Pierre-Bénite, , France
Research Site
Toulon Armees, , France
Research Site
Bad Berka, , Germany
Research Site
Donaustauf, , Germany
Research Site
Frankfurt, , Germany
Research Site
Gauting, , Germany
Research Site
Göttingen, , Germany
Research Site
Halle, , Germany
Research Site
Hanover, , Germany
Research Site
Karlsruhe, , Germany
Research Site
Leipzig, , Germany
Research Site
Löwenstein, , Germany
Research Site
Mannheim, , Germany
Research Site
München, , Germany
Research Site
Hong Kong, , Hong Kong
Research Site
Jerusalem, , Israel
Research Site
Kfar Saba, , Israel
Research Site
Tel Litwinsky, , Israel
Research Site
Ẕerifin, , Israel
Research Site
Ancona, , Italy
Research Site
Bologna, , Italy
Research Site
Catania, , Italy
Research Site
Genova, , Italy
Research Site
Milan, , Italy
Research Site
Orbassano, , Italy
Research Site
Parma, , Italy
Research Site
Roma, , Italy
Research Site
Rozzano, , Italy
Research Site
S.Andrea Delle Fratte, , Italy
Research Site
Sondalo, , Italy
Research Site
Udine, , Italy
Research Site
México, , Mexico
Research Site
Zapopan, , Mexico
Research Site
Saint Maartenskliniek, , Netherlands
Research Site
Lima, , Peru
Research Site
Cebu City, , Philippines
Research Site
Manila, , Philippines
Research Site
Quezon City, , Philippines
Research Site
Singapore, , Singapore
Research Site
Goyang-si, , South Korea
Research Site
Seongnam, , South Korea
Research Site
Seoul, , South Korea
Research Site
Suwon, , South Korea
Research Site
Baracaldo(Vizcaya), , Spain
Research Site
Barcelona, , Spain
Research Site
Santander, , Spain
Research Site
Valencia, , Spain
Research Site
Changhua, , Taiwan
Research Site
Kaohsiung City, , Taiwan
Research Site
Kaohsiung Hsien, , Taiwan
Research Site
Liou Ying Township, , Taiwan
Research Site
Taichung, , Taiwan
Research Site
Taipei, , Taiwan
Research Site
Taoyuan District, , Taiwan
Research Site
Bangkok, , Thailand
Research Site
Chiang Mai, , Thailand
Research Site
Khon Kaen, , Thailand
Research Site
Birmingham, , United Kingdom
Research Site
Chelmsford, , United Kingdom
Research Site
Dundee, , United Kingdom
Research Site
Maidstone, , United Kingdom
Research Site
Manchester, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Platt A, Morten J, Ji Q, Elvin P, Womack C, Su X, Donald E, Gray N, Read J, Bigley G, Blockley L, Cresswell C, Dale A, Davies A, Zhang T, Fan S, Fu H, Gladwin A, Harrod G, Stevens J, Williams V, Ye Q, Zheng L, de Boer R, Herbst RS, Lee JS, Vasselli J. A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies. BMC Cancer. 2015 Mar 23;15:171. doi: 10.1186/s12885-015-1146-8.
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EUDRACT Number 2006-002384-12
Identifier Type: -
Identifier Source: secondary_id
D4200C00044
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.